Skip to main content
Erschienen in: Clinical and Translational Oncology 5/2019

17.10.2018 | Research Article

Impact of rectum and bladder anatomy in intrafractional prostate motion during hypofractionated radiation therapy

verfasst von: M. Roch, A. Zapatero, P. Castro, D. Büchser, L. Pérez, D. Hernández, C. Ansón, M. Chevalier, F. García-Vicente

Erschienen in: Clinical and Translational Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The objective was to determine the magnitude of the prostate intrafractional motion relative to bony pelvis anatomy, and to evaluate the relationship between this displacement and some clinical and anatomical variables.

Materials and methods

The prospective study consisted of 544 images (375 pre-treatment CBCT and 169 post-treatment CBCT) from 15 prostate adenocarcinoma patients that were used for intrafractional prostate motion determination. In addition, two radiation oncologists re-contoured the bladder and rectum on each CBCT according to the patient’s anatomy of the day. ANOVA and correlation analysis followed by linear regression analysis were performed to identify clinical or anatomical variables that predict large prostate intrafractional motion.

Results

Prostate shift increased in patients with hormone therapy (p ≤ 0.02). The regression analysis showed that patients with large bladder intrafractional filling (p < 0.01) and a large bladder volume difference from planning CT were more likely to experience bigger longitudinal prostate motion (> 3 mm). Recommended bladder size values: anterior–posterior size ≤ 10 cm and anterior–posterior/cranio-caudal ratio ≤ 1.7, both parameters measured in the midsagittal prostate plane, were defined.

Conclusions

The treatment margin should not be reduced for those patients who were treated with hormone therapy and/or whose rectum or bladder was far from complying the preparation protocol conditions.
Literatur
5.
Zurück zum Zitat Ghilezan M, Yan D, Liang J, Jaffray D, Wong J, Martinez A. Online image-guided intensity-modulated radiotherapy for prostate cancer: how much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery. Int J Radiat Oncol Biol Phys. 2004;60:1602–10. https://doi.org/10.1016/j.ijrobp.2004.07.709.CrossRefPubMed Ghilezan M, Yan D, Liang J, Jaffray D, Wong J, Martinez A. Online image-guided intensity-modulated radiotherapy for prostate cancer: how much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery. Int J Radiat Oncol Biol Phys. 2004;60:1602–10. https://​doi.​org/​10.​1016/​j.​ijrobp.​2004.​07.​709.CrossRefPubMed
13.
Zurück zum Zitat Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goser. Clin Oncol (R Coll Radiol). 2013;25:190–6. https://doi.org/10.1016/j.clon.2012.09.010.CrossRef Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goser. Clin Oncol (R Coll Radiol). 2013;25:190–6. https://​doi.​org/​10.​1016/​j.​clon.​2012.​09.​010.CrossRef
Metadaten
Titel
Impact of rectum and bladder anatomy in intrafractional prostate motion during hypofractionated radiation therapy
verfasst von
M. Roch
A. Zapatero
P. Castro
D. Büchser
L. Pérez
D. Hernández
C. Ansón
M. Chevalier
F. García-Vicente
Publikationsdatum
17.10.2018
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 5/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1960-y

Weitere Artikel der Ausgabe 5/2019

Clinical and Translational Oncology 5/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.